Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
Heat-shock proteins (HSP) are important molecules in the pathogenesis of multiple myeloma (MM). Their blockages by drugs or cellular immune response have been investigated, and a possible association with the presence of oligoclonal bands (OB) has been postulated in patients with MM after allogenic stem cell transplantation. The aim of the present study was to ascertain the serum antibody levels against three HSP (60, 70 and 90) by ELISA in patients with MM in complete remission after autologous stem cell transplantation (ASCT), with or without OB, and compare them with those patients with stable gammopathy of undetermined significance (MGUS) and healthy controls. Our results in samples after ASCT showed no differential levels of anti-HSP according to the presence or absence of the oligoclonal response. However, higher levels of anti-HSP90 were found in patients with stable MGUS in comparison with MM patients (p = 0.004). In the same line, a longer progression-free survival was observed in those patients who presented higher anti-HSP90 levels after ASCT (p = 0.042). These results suggest, for first time, the potential of anti-HSP90 humoral immune response for long-term control of malignant plasma cell disorders.
Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Natalia
N
Tovar
Carlos
C
Fernández de Larrea
Fabiola
F
Pedrosa
Juan I
JI
Aróstegui
Ma Teresa
MT
Cibeira
Laura
L
Rosiñol
Montserrat
M
Elena
Xavier
X
Filella
Jordi
J
Yagüe
Joan
J
Bladé
D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D000918:Antibody Specificity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001323:Autoantibodies / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D001324:Autoantigens / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D018834:Chaperonin 60 / Q000276:immunology*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D018840:HSP70 Heat-Shock Proteins / Q000276:immunology*; D018841:HSP90 Heat-Shock Proteins / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000097:blood / Q000276:immunology; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery; D009363:Neoplasm Proteins / Q000276:immunology*; D043025:Oligoclonal Bands / Q000097:blood / Q000276:immunology*; D011719:Pyrazines / Q000008:administration & dosage; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage; D014182:Transplantation, Autologous
D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D001897:Boronic Acids; D018834:Chaperonin 60; D005938:Glucocorticoids; D018840:HSP70 Heat-Shock Proteins; D018841:HSP90 Heat-Shock Proteins; D009363:Neoplasm Proteins; D043025:Oligoclonal Bands; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D008558:Melphalan